Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA regarding its NDA for Troriluzole in spinocerebellar ataxia, the firm removed Troriluzole and updated its model following Q3 results. The next catalyst for the stock is Opakalim Phase 2 data in major depressive disorder that is expected in Q4, the analyst tells investor
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges
- Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
- Biohaven Ltd. Raises $200M in Public Offering
- Biohaven price target lowered to $14 from $28 at Citi
- Strategic Focus and Financial Positioning Drive Buy Rating for Biohaven Ltd.